Abstract:Background For ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) patients, tumor necrosis factor (TNF) inhibitors are recommended when disease activity persists despite non-steroidal anti-inflammatory drugs. Objectives To evaluate the efficacy and safety of TNF inhibitors in patients with AS and nr-axSpA. Methods Searching PubMed, Embase, Cochrane Library, CNKI and WanFang databases, we included all double-blind randomized controlled trials (RCTs) that compared a TNF inhibitor with placebo in AS/nr-axSpA patients. The efficacy endpoints included the proportions of patients reaching Assessment in Ankylosing Spondylitis 20% response (ASAS20), ASAS5/6, partial remission, and Bath Ankylosing Spondylitis Disease Activity Index 50% improvement (BASDAI50). We used adverse events (AEs), withdrawals due to AEs and severe AEs to evaluate the safety of biologics. TNF inhibitors were pooled to perform comparison with placebo and among themselves, calculating odds ratios (OR) with associated 95% credible intervals (CrI), probability of being best (Pbest) and the surface under the cumulative ranking curve (SUCRA) as well as numbers needed to treat (NNT). Results Twenty-nine double-blind RCTs with 5200 patients were included in the analysis focusing on 6 TNF inhibitors, including etanercept, intended copies of etanercept, adalimumab, infliximab, golimumab and certolizumab. Compared with placebo, TNF inhibitors were efficacious in achieving ASAS20, ASAS5/6, partial remission and BASDAI50 responses, but with an increased risk of AEs and withdrawals due to AEs. No significant differences in efficacy were found among biologics, except that etanercept had a higher rate of ASAS20 response compared with golimumab in the Chinese patients (OR 4.78, 95% CrI 1.20–17.84). Among the Chinese population, etanercept was ranked the most efficacious therapy for ASAS20 with NNT of 2 (Pbest 93.6%, SUCRA 0.97). Conclusions Compared to placebo, TNF inhibitors are efficacious in controlling disease activity for AS and nr-axSpA patients without a higher risk of severe AEs. Although no significant differences in efficacy among biologics were found, the Chinese population had a better ASAS20 response to etanercept. References Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis care & research 2015. Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis and rheumatism 2009;60:717–27. Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. The Cochrane database of systematic reviews 2015;4:Cd005468. Callhoff J, Sieper J, Weiss A, et al. Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Annals of the rheumatic diseases 2015;74:1241–8. Disclosure of Interest None declared

Comparing Tapering Strategy to Standard Dosing Regimen of Recombinant Human Tumor Necrosis Factor Receptor-Ig Fusion Protein for Injection in Patients with Ankylosing Spondylitis in Low Disease Activity

Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis

Disease Activity Guided Stepwise Tapering or Discontinuation of Rhtnfr:Fc, an Etanercept Biosimilar, in Patients with Ankylosing Spondylitis: a Prospective, Randomized, Open-Label, Multicentric Study

Comparison of safety and efficac y of short-term treatment between re-use and initial use in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors

Clinical Observation on Recombinant Human TypeⅡTumor Necrosis Factor Receptor-antibody Fusion Protein and Immunosuppressive Agents in Treatment of Patients with Ankylosing Spondylitis

Efficacy and Safety of a Novel Recombinant Human Tumor Necrosis Factor-Α Receptor Ⅱ : Fc Fusion Protein in Chinese Patients with Active Ankylosing Spondylitis: Results of a Randomized, Double-Blind,multicenter Trial

AB0662 Indirect Comparison of TNF Inhibitors for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials

Treatment of Ankylosing Spondylitis with Recombinant Hnman Tumor Necrosis Factor-Fc Fusion Protein (etanercept) : a Multicenter, Randomized, Double-Blind, Placebo-Con-trolled Trial

Concurrent Intervention with Exercises and Stabilized Tumor Necrosis Factor Inhibitor Therapy Reduced the Disease Activity in Patients with Ankylosing Spondylitis

Indirect Comparison of Anti-Tnf-α Agents for Active Ankylosing Spondylitis: Mixed Treatment Comparison of Randomized Controlled Trials.

Clinical Effect of Recombinant Human Type Ⅱ Tumor Necrosis Factorreceptor-Antibody Fusion Protein in Treatment of Ankylosing Spondylitis

A short-term study on half-value dose and decrement etanercept plus conventional therapy in active ankylosing spondylitis

The Ankylosing Spondylitis Disease Activity Score Is A Highly Discriminatory Measure Of Disease Activity And Efficacy Following Tumour Necrosis Factor-Alpha Inhibitor Therapies In Ankylosing Spondylitis And Undifferentiated Spondyloarthropathies In China

The Cost-effective Analysis of TNF-αInhibitors in the Treatment of Rheumatoid Arthritis

Effective Serum Level of Etanercept Biosimilar and Effect of Antidrug Antibodies on Drug Levels and Clinical Efficacy in Chinese Patients with Ankylosing Spondylitis.

A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China

Population Pharmacokinetics of Rhtnfr-Fc in Healthy Chinese Volunteers and in Chinese Patients with Ankylosing Spondylitis

Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial

Tumor Necrosis Factor-a-308 Gene Polymorphism Affects the Therapeutic Efficacy of Etanercept on Ankylosing Apondylitis

Comparative Efficacy of Advanced Therapies in the Treatment of Radiographic Axial Spondyloarthritis or Ankylosing Spondylitis as Evaluated by the ASDAS Low Disease Activity Criteria

Recombinant Human Tumor Necrosis Factor Receptor Type Ⅱ - IgG Fc Fusion Protein for the Treatment of Moderate to Severe Psoriasis Vulgaris:A Multicenter, Randomized, Parallel-Group, Controlled Clinical Trial